Defibrillation effects of intravenous nifekalant in patients with out-of-hospital ventricular fibrillation.

@article{Igarashi2005DefibrillationEO,
  title={Defibrillation effects of intravenous nifekalant in patients with out-of-hospital ventricular fibrillation.},
  author={Masaki Igarashi and Tadashi Fujino and Miwako Toyoda and Keishi Sugino and Kenichirou Sasao and Shuichi Sasamoto and Takayuki Otsuka and Kenzaburo Kobayashi and Yoshifumi Okano and Katsunori Yosiwara and Nobuya Koyama},
  journal={Pacing and clinical electrophysiology : PACE},
  year={2005},
  volume={28 Suppl 1},
  pages={S155-7}
}
Nifekalant (NF), a pure K(+) channel blocker developed in Japan, has been reported to be effective in the treatment of life-threatening ventricular arrhythmias. We studied its efficacy in 18 men and 4 women with out-of-hospital ventricular fibrillation (VF) admitted to our emergency department between August 2001 and March 2004. The number of DC shocks delivered for out-of-hospital VF, serum Na(+) and K(+), arterial blood pH, and base excess were compared in 8 patients treated with NF, 0.3 mg… CONTINUE READING